Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosed with Myasthenia Gravis at least 6 months (180 days) prior to the date of the Screening Visit as confirmed by specific criteria.~2. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening.~3. MG-ADL profile must be ≥ 6 at screening and randomization (Day 1).~4. Vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug to reduce the risk of meningococcal infection (N meningitidis).~Exclusion Criteria:~Medical Conditions~1. Any active or untreated thymoma. History of thymic carcinoma or thymic malignancy unless deemed cured by adequate treatment with no evidence of recurrence for ≥ 5 years before screening.~2. History of thymectomy within the 12 months prior to screening.~3. History of N meningitidis infection.~4. Use of the following within the time period specified below:~   * IV immunoglobulin within 4 weeks of randomization~  * Use of plasma exchange within 4 weeks of randomization~  * Use of rituximab within 6 months of screening~5. Participants who have received previous treatment with complement inhibitors (for example, eculizumab).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ravulizumab (Type: EXPERIMENTAL): Participants will receive ravulizumab for the duration of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during the 26-week randomized-controlled period of the study, after which they will enter the open-label extension period of the study and receive ravulizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).